These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36497329)

  • 41. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
    Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
    J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).
    Mukund A; Bhardwaj K; Choudhury A; Sarin SK
    J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.
    Cheung AH; Lam CS; Tam HS; Cheung TT; Pang R; Poon RT
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):493-498. PubMed ID: 27733318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis.
    Yao M; Cheng S; Zhai X; Zhao H; Hong J; Li X; Meng Y; Chen W
    Appl Bionics Biomech; 2022; 2022():9084852. PubMed ID: 36091626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma.
    Razi M; Safiullah S; Gu J; He X; Razi M; Kong J
    J Interv Med; 2022 Feb; 5(1):10-14. PubMed ID: 35586278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma].
    Chen G; Zhang D; Ying Y; Wang Z; Tao W; Zhu H; Zhang J; Peng Z
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):44-51. PubMed ID: 28436630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Shi Q; Chen D; Zhou C; Liu J; Huang S; Yang C; Xiong B
    Cancer Manag Res; 2020; 12():5461-5468. PubMed ID: 32753963
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conventional
    Song JE; Kim DY
    World J Hepatol; 2017 Jun; 9(18):808-814. PubMed ID: 28706579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
    Zhao C; Ma SPZCY
    J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
    Bi Y; Ren K; Ren J; Ma J; Han X
    Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827
    [No Abstract]   [Full Text] [Related]  

  • 52. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
    Huang J; Huang W; Zhan M; Guo Y; Liang L; Cai M; Lin L; He M; Lian H; Lu L; Zhu K
    J Hepatocell Carcinoma; 2021; 8():1445-1458. PubMed ID: 34858889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
    Guo J; Wang W; Zhang Y; Xu L; Kong J
    J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis.
    Bargellini I; Lorenzoni V; Lorenzoni G; Scalise P; Andreozzi G; Bozzi E; Giorgi L; Cervelli R; Scandiffio R; Perrone O; Meccia DV; Boccuzzi A; Daviddi F; Cicorelli A; Lunardi A; Crocetti L; Turchetti G; Cioni R
    Eur Radiol; 2021 Oct; 31(10):7512-7522. PubMed ID: 33871708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study.
    Ouyang T; Liu J; Shi C; Zhu L; Guo X
    J Hepatocell Carcinoma; 2021; 8():1459-1471. PubMed ID: 34858890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
    Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
    Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma.
    Fateen W; Khan F; O'Neill RJ; James MW; Ryder SD; Aithal GP
    J Hepatocell Carcinoma; 2017; 4():123-130. PubMed ID: 29082223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
    Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
    Front Immunol; 2022; 13():940009. PubMed ID: 35874708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.